Skip to main content
Year archive

Immuron Ltd — 2016 filings

All 59 regulatory filings released by Immuron Ltd (IMRN) in 2016, sourced directly from the official regulator.

59 Filings
2016 Period
2016 filings (59)
Filing Released Lang
Immuron Files Form F-1 with the SEC 287 pages 2.0MB
Capital/Financing Update
2016-12-21 English
F-1
Regulatory Filings
2016-12-21 English
Appendix 3B - Issue of Options Under ESOP 12 pages 207.8KB
Capital/Financing Update
2016-12-08 English
Form 604 - Change in Substantial Shareholding (Grandlodge) 3 pages 45.7KB
Major Shareholding Notification
2016-12-06 English
Appendix 3B - Issue of Rights Issue Options & ESOP Shares 12 pages 192.3KB
Capital/Financing Update
2016-12-01 English
Appendix 3Y - Change of Director's Interest Notices (x4) 8 pages 1.5MB
Director's Dealing
2016-12-01 English
Immuron Receives $1.6M R&D Tax Concession Refund 1
Regulatory Filings
2016-11-28 English
2016 AGM Presentation 17 pages 1.3MB
AGM Information
2016-11-28 English
Results of 2016 Annual General Meeting 1 page 399.7
Declaration of Voting Results & Voting Rights Announcements
2016-11-28 English
Immurons NASH Phase II Trial Achieves 100 Patient Milestone 2 pages 108.5KB
Regulatory Filings
2016-10-27 English
Notice of 2016 Annual General Meeting 20 pages 291.3KB
AGM Information
2016-10-27 English
Appendix 3Y - Change in Director's Interest Notice (DP) 2 pages 374.6KB
Director's Dealing
2016-10-26 English
Becoming a substantial holder 4 pages 57.5KB
Major Shareholding Notification
2016-10-16 English
NASH Phase II Trial reaches 75% of Patient Recruitment 3 pages 112.3KB
Regulatory Filings
2016-10-09 English
NASH Assets In Demand - Allergan Acquires Tobira for US$1.7B 2 pages 106.0KB
M&A Activity
2016-10-04 English
Immurons $6M Rights Issue Closes Oversubscribed 2 pages 98.8KB
Capital/Financing Update
2016-10-03 English
IMC - ASX - Appendix 3B (Rights Issue) 11 pages 167.1KB
Capital/Financing Update
2016-10-03 English
Immuron Expands Collaborate with US Navy 3 pages 471.6KB
Regulatory Filings
2016-08-29 English
Appendix 4E and Annual Report 73 pages 1.9MB
Annual Report FY 2016
2016-08-29 English
Appendix 4G 10 pages 346.7KB
Regulatory Filings
2016-08-29 English
US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH 2 pages 119.2KB
Regulatory Filings
2016-08-17 English
Travelan to be Stocked by US Distributor Medique Products 2 pages 99.2KB
Regulatory Filings
2016-08-07 English
Immuron to Seek Approval of Rights Issue Options at AGM 2 pages 89.0KB
Capital/Financing Update
2016-08-01 English
Immuron to Cooperate with Universities on Autism Research 2 pages 457.8KB
Regulatory Filings
2016-07-19 English
Immuron to repay outstanding Convertible Note in cash 2 pages 97.6KB
Capital/Financing Update
2016-07-17 English
Form 604 -Change in Substantial Shareholding (Inverarey P/L) 4 pages 74.4KB
Major Shareholding Notification
2016-07-14 English
Appendix 3Y - Change in Director's Interest Notices (x4) 8 pages 92.9KB
Director's Dealing
2016-07-10 English
Appendix 3B for Rights Issue & New Top 20 Shareholder List 12 pages 214.7KB
Capital/Financing Update
2016-07-06 English
Immuron Rights Issue Raises $5.33M 2 pages 104.1KB
Capital/Financing Update
2016-07-04 English
IMC Signs Shigella Vaccine Developmt Agreement with US Army 3 pages 102.9KB
Capital/Financing Update
2016-06-20 English
Immuron Newsletter - June 2016 5 pages 2.1MB
Investor Presentation
2016-06-19 English
Travelan and Protectyn Are Now Available For Sale in China 2 pages 321.7KB
Regulatory Filings
2016-06-15 English
Travelan to Reach Upto 1.5M New US Customers via Magellans 2 pages 91.9KB
Regulatory Filings
2016-06-13 English
Immuron Extends Closing Date of $6M Rights Issue 2 pages 81.1KB
Capital/Financing Update
2016-06-13 English
Immuron Announces $6M Rights Issue Offer 4 pages 139.5KB
Capital/Financing Update
2016-05-30 English
Appendix 3B & 708A Notice 11 pages 184.7KB
Capital/Financing Update
2016-05-30 English
Section 708AA Notice (Rights Issue) 3 pages 108.3KB
Capital/Financing Update
2016-05-30 English
Letter to Optionholders Regarding Rights Issue (May 2016) 3 pages 99.0KB
Capital/Financing Update
2016-05-30 English
Letter to Eligible Shareholders Regarding Rights Issue 3 pages 99.2KB
Capital/Financing Update
2016-05-30 English
Letter to Ineligible Shareholders Regarding Rights Issue 3 pages 98.6KB
Capital/Financing Update
2016-05-30 English
Immuron Rights Issue Offer Booklet (May 2016) 29 pages 316.5KB
Capital/Financing Update
2016-05-30 English
Immuron Company Presentation - May 2016 43 pages 3.2MB
Investor Presentation
2016-05-30 English
Trading halt 2 pages 138.4KB
Capital/Financing Update
2016-05-26 English
NASH Phase II Trial Reaches 50% Recruitment Milestone 2 pages 92.5KB
Regulatory Filings
2016-05-24 English
Appendix 3B & 708A Notice 11 pages 179.0KB
Capital/Financing Update
2016-05-15 English
Immuron Announces E-Commerce Agreement with QBID in China 3 pages 113.9KB
Regulatory Filings
2016-05-08 English
US Distribution Reach Expanded through McKesson 2 pages 404.4KB
Regulatory Filings
2016-04-27 English
US Travelan Sales Network Widened by Allocation Inc Ptnrship 2 pages 104.6KB
Regulatory Filings
2016-04-18 English
Appendix 3B & 708A Notice 11 pages 180.1KB
Capital/Financing Update
2016-04-17 English
Expansion of US Travelan Sales Following CVS Pharmacy Launch 2 pages 101.8KB
Regulatory Filings
2016-04-13 English
Appendix 3B - Issuance of Securities 11 pages 186.6KB
Capital/Financing Update
2016-04-12 English
Appendix 4D - Half Yearly Report and Accounts 22 pages 1.7MB
Interim / Quarterly Report H1 2016
2016-02-24 English
Appendix 3B - Issue of Securities 11 pages 181.4KB
Capital/Financing Update
2016-02-23 English
Immuron Initiates Pre-Clinical Colitis Development Program 2 pages 100.0KB
Capital/Financing Update
2016-02-21 English
Immuron Secures upto $1.7M Equity & Convertible Note Funding 2 pages 99.9KB
Capital/Financing Update
2016-02-16 English
Immuron Receives $1.47M R&D Tax Concession Refund 1
Regulatory Filings
2016-02-03 English
US Analyst Reports on Immuron Products and R&D Pipeline 2 pages 83.2KB
Regulatory Filings
2016-02-02 English
Analyst Reports on Immuron IMM-529 C. difficile Program 1
Regulatory Filings
2016-01-13 English
IMC Achieves Outstanding Results in C-Diff Recurrence Study 3 pages 116.3KB
Regulatory Filings
2016-01-11 English